Introduction {#s1}
============

Acute leukemia is a kind of hematological malignancy with high mortality and poor prognosis and it requires a complex and highly diversified treatment because of its wide prognostic heterogeneity. Although traditional treatments such as chemotherapy and hematopoietic stem cell transplantation make patients obtain complete remission, patients will eventually develop relapse and resistance, leading to disease progression. The average cure rate was only 35% in adult acute lymphoblastic leukemia (ALL) patients and 40% in aged ≤65 years acute myeloid leukemia (AML) patients relying on traditional treatment ([@B1], [@B2]). Allogenic hematopoietic stem cell transplantation (allo-HSCT) increases the cure rate of ALL to about 50%, and offers significant relapse-free survival and overall survival benefits for intermediate- and poor-risk AML, and also cures a proportion of patients with refractory/relapsed AML, but transplantation related mortality (TRM) has reached 20--30% ([@B1], [@B3]--[@B6]). In fact, allo-HSCT is also a form of immunotherapy through graft-vs.-leukemia (GvL) effects by the adoptively transferred donor T-cells, which is seen as the first successful clinical application of immunotherapy. Based on GvL effects, the non-myeloablative allogeneic stem cell transplantation has been developed, thus reducing TRM ([@B7]). Some anti-AML drugs such azacytidine and sorafenib have shown to promote GvL effects without increasing the risk of graft-vs.-host disease (GVHD) by regulating immune cells ([@B8]--[@B10]). Besides, donor lymphocyte infusions (DLI) as a form of pure immunotherapy not only could prevent recurrence after transplantation but also have cured a number of acute leukemia patients ([@B11]). Therefore, immune related intervention plays a key role in the treatment of acute leukemia.

In recent years, the emergence of immunotherapy has brought hope to hematological malignancies. Here, we reviewed the research progress of immunotherapy in acute leukemia. Immunotherapy mainly includes targeting AML/ALL cell surface antigen (such as CD33, CD123, CLL-1 on AML and CD20, CD19, CD52 on ALL), relieving T/NK cell immunosuppression (such as PD1/PD-L1, CTLA4), using immunopotentiator (such as OX40 agonist) and adoptive cell therapy (such as CART), etc. This study focused on the naked monoclonal antibodies (mAbs), antibody-drug conjugate (ADC), bispecific T cell engager (BiTE), chimeric antigen receptor (CAR) T/NK cell, immune checkpoint inhibitor/immune agonist, etc. An overview of immunotherapy targets for AML and ALL is shown in [Figure 1](#F1){ref-type="fig"}.

![An overview of immunotherapy targets for acute myeloid leukemia and acute lymphoblastic leukemia. Myeloid tumor cell surface antigen targets include CLL-1, CD123, CD33, CD133, PR1/HLA-A2, VEGF-C, and FLT3. Anti-CLL-1 ADC, an antibody-drug conjugate (ADC) targeting CLL-1 that binds to pyrrole diazepine dimer. MCLA-117 is a full-length human IgG1 Bi-Specific T-cell Engagers (BiTE) targeting CLL-1 and CD3. CD3/CLL1 TDB, a CD3 T-cell-dependent bispecific (TDB) full-length humanized IgG1 antibody targeting CLL1. CSL360 and CSL362 are recombinant chimeric antibody targeting CD123 and fully humanized anti-CD123 antibody, respectively. SL-101, an CD123 ADC fused to Pseudomonas exotoxin A. MGD006 is a bispecific CD3xCD123 dual-affinity re-targeting (DART) molecule. XmAb14045, a structured anti-CD123 T cell recruitment antibody. GO, SGN-CD33A, and IMGN779 are CD33 ADC binding to N-acetylgamma-erythromycin, pyrrolidone dimer and DNA alkylation activity, respectively. AMG 330 is a CD33/CD3 BiTE and AMG 673 is the second CD33/CD3 BiTE. CD33/CD3 TandAbs is a directional tandem tetravalent bispecific antibody. CD16/CD33 BiKE is a Bi-Specific Killer Engagers (BiKE) targeting CD16 and CD33, and 161533 TriKE is a Tri-Specific Killer Engagers (TiKE) including a modified IL-15 crosslinking agent between CD 16 and CD 33 single-chain Fv fragments. PD-1EX with CD3xCD33 BiTE, fused the PD-1 extracellular domain (PD-1EX) with CD3xCD 33 BiTE. Hu8F4, a T-cell receptor-like monoclonal antibody targeting PR1/HLA-A2. PR1/HLA-A2 CART, PR1/HLA-A2-specific CART (h8F4-CAR-T cells), containing the scFv of h8F4 fused to CD3 zeta chain through the co-stimulatory domain of CD28. Anti-VEGF-C, an antibody targeting vascular endothelial growth factor C to reduce expansion and enhance differentiation. FLYSYN and 293 C3-SDIE are antibodies targeting FLT3 and CD133. Compound CART include 123b-33bc CART simultaneously targeting CD123 and CD33, and CD123/CLL1 CART simultaneously targeting CD123 and CLL1. Lymphoid tumor cell surface antigen targets include CD52, CD20, CD19, CD22, CD10. Rituximab and Ofatumumab are antibodies targeting CD20. CD20-TDB, is a CD3 TDB full-length humanized immunoglobulin G1 molecule targeting CD20. SAR 3419, SGN-CD19A, and SGN-CD19B are CD 19 ADC that binds to Maytansin, Monoinositol F and Pyrrolidine diazepine, respectively. Blinatumomab, a BiTE with dual specificity for CD19 and CD3. CARCIK-CD19, a cytokine-induced killer (CIK) cells transfected with the transposon CD19CAR. Epratuzumab and Inotuzumab ozogamicin are unconjugated human antibody targeting CD22 and humanized anti-CD 22 ADC, respectively. Alemtuzumab, an anti-CD52 antibody. Compound CART include CD19/CD20 CART simultaneously targeting CD19 and CD20, and CD19/CD22 CART simultaneously targeting CD19 and CD22. Immune targets include inhibitory receptors programmed cell death protein 1 (PD1), cytotoxic T-lymphocyte antigen 4 (CTLA4), T-cell immunoglobulin and mucin-domain containing-3 (TIM3), and stimulatory receptors OX40 on T-cell subsets and their ligands (PD-L1, PD-L2, B7, and OX40L) on AML blasts. IPH2101, anti antibody targeting KIR on NK cell surface.](fonc-09-00917-g0001){#F1}

Unconjugated Antibodies/Antibody-Drug Conjugate (ADC) {#s2}
=====================================================

Monoclonal antibody binding to leukemia target antigen can lead to direct apoptosis, complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) ([@B12]). Potential targets for the treatment of AML include CD33, CD45, CD96, CD123, CD135, C-type lectin-like molecule-1 (CLL1), and FLT3 and so on, among of which CD33 and CD123 also expressed on hematopoietic stem cells (HSCs) while CLL1 absent on megakaryocytic progenitor cells and CD34+/CD38-HSCs ([@B13]). The potential targets for ALL include CD19, CD20, CD22, and CD52 *etc*. ([@B12], [@B14]--[@B16]). Antibody therapy include unconjugated antibodies and ADC. ADC can deliver a more potent cytotoxic payload specifically targeting leukemia cells accompanying the conjugated monoclonal antibody if a surface marker to internalize upon binding, and maintain lower systemic concentrations to enhance the effectiveness of induction chemotherapy.

Anti-CD33 Antibody
------------------

CD33 is a transmembrane cell surface receptor and a member of the sialic acid-binding immunoglobulin (Ig)-like lectins, containing two conserved tyrosine-based inhibitory signaling motifs for recruitment and activation of the tyrosine phosphatases SHP-1 and SHP-2 or suppressor of cytokine signaling 3 ([@B17]). CD33 widely expressed on AML blasts about 90%, and on normal multi-potent myeloid precursor cells, unipotent myeloid colony-forming cells, and maturing myeloid cells, monocytes, peripheral granulocytes and so on ([@B18]).

### Gemtuzumab Ozogamicin (GO)

GO is the first recombinant humanized ADC targeting CD33, which is linked to N-acetyl-γ-carramycin delivering a DNA-damaging calicheamicin derivative. In 2000, FDA approved GO for recurrent CD 33 + AML aged 60 years or older ([@B19]). But in the confirmed III phase clinical study of SWOG S 0106, the addition of GO to induction therapy or after consolidation did not improve the CR rate, DFS or OS, and the mortality rate of GO group increased, so GO automatically withdrew from the market ([@B20]). In subsequent studies, it was confirmed that adding GO benefits OS in patients with good cytogenetics and reduces the risk of recurrence ([@B21], [@B22]). Although GO has shown a narrow therapeutic window in early clinical studies, recent reports have proved that the improved dose regimen of GO combined with induced chemotherapy was safe and provided significant survival value for AML patients. Cathy C Zhang has shown that low dose GO combined with induced chemotherapy was able to remove minimal residual diseases more effectively, including LICs, thus achieving a more lasting remission effect and improving the survival of model mice ([@B23]). In the randomized phase III EORTC-GIMEMA AML-19 study, for the elderly patients who were not suitable for intensive chemotherapy in the initial treatment of AML, the use of low dose GO was better than the best support therapy in improving OS (4.9 months vs. 3.6 months; HR = 0.69; 95% CI, 0.53\~0.90; *p* = 0.005). The side effects in the two groups were similar and the toxicity was controllable ([@B24]). The randomized phase III ALFA 0701 trial showed that adding reduced or segmented doses of GO to standard first-line chemotherapy significantly improved the event-free survival rate in primary AML patients (13.6 months vs. 8.8 months; HR = 0.68; 95% CI, 0.51\~0.91) ([@B25]). Based on the above two studies, on September 1, 2017, FDA approved GO for the treatment of CD 33 positive adult AML ([@B26]). The expression of CD 33 is considered to be a predictor of the efficacy of GO in adult AML ([@B27]). The clinical study of stage III in Children\'s Oncology Group Trial AAML0531 showed that CD 33 splicing polymorphism determined the response of GO to primary AML, especially for CC genotype patients, to conclude that the recurrence rate of GO group was significantly lower than that of non-GO group (26% vs. 49%, *p* \< 0.001) ([@B28]). In order to improve the therapeutic response, GO combined with epigenetics therapy is also being studied. For example, in clinical trials of GO combined with histone deacetylase inhibitor Vorinostat and DNA methyltransferase I inhibitor Azacitidine in elderly patients with relapsed or refractory (r/r)AML phase I/II, the ORR was as high as 41.9% in patients receiving maximum tolerated dose ([@B29]).

### SGN-CD33A

An ADC targeting CD33 conjugated to a highly potent, synthetic DNA cross-linking pyrrolobenzodiazepine (PBD) dimer via a protease-cleavable linker leading to cell death. SGN-CD33A overcome some limitations of GO, such as the non-uniform conjugation of the toxin with the antibody, the drug\'s relatively slow internalization kinetics, and toxin extrusion via drug transporters ([@B30]). In combination with hypomethylating agents (HMAs) treating AML patients, the remission rate was significantly increased, but the hematological toxicity was increased at the same time ([@B31]). SGN-CD33A has been reported to cause liver damage, especially sinusoidal syndrome, which has been terminated by FDA. Dose-adjusted SGN-CD33A can reduce adverse reactions. Phase I clinical studies are under way to assess its toxicity and efficacy ([@B32]).

### IMGN779

Another preclinical studies of anti-CD-33 antibodies, a conjugate with DNA alkylation activity, possessing good antitumor effects in mouse model and AML cell lines, whose cytotoxic activity involved DNA damage, cell-cycle arrest, and apoptosis ([@B33]). In order to improve the specificity of target cells for AML, alternative target antigens, such as CD25, FLT3 in the early clinical stage, are being studied ([@B34], [@B35]).

Anti-CD123 Antibody
-------------------

Interleukin-3 (IL-3) receptor α (CD123) is not only constitutively expressed on normal committed hematopoietic progenitor cells, but also highly expressed in AML blasts, including leukemic stem cells (LSCs) ([@B36], [@B37]). IL-3 is an activated T cell product that bridges innate and adaptive immunity and contributes to several immunopathologies.

### CSL360

CSL 360 is a recombinant chimeric immunoglobulin G 1 anti CD123 monoclonal antibody, which can recognize the CD123(+)/CD131(--) phenotype expressed by LSCs exhibiting anti leukemia activity by neutralizing IL-3 to prevent IL-3 binding to its receptor ([@B38], [@B39]). *In vitro*, blockade of CD123 in AML cell lines abolishes proliferation induced by IL-3 ([@B39], [@B40]). Stage I clinical trials proved its safety, but it did not show definite anti-leukemia activity in most patients with AML ([@B38]). CSL360 modified with diethylenetriaminepentaacetic acid for complexing 111In and 13-mer nuclear translocation sequence peptides to enable nuclear importation in LSCs for Auger electron radioimmunotherapy of AML was studied by Leyton et al. ([@B41]).

### CSL362

The second generation humanized, affinity-matured and Fc-engineered anti CD123 monoclonal antibody, induces stronger ADCC by high affinity to CD16 of NK cells ([@B42], [@B43]). Several studies have proved that it has good antitumor activity in mice and can prolong the survival time of mice ([@B42], [@B44]). Xie et al. reported a case of leukemia cell resistant to autologous ADCC. After allogeneic hematopoietic stem cell transplantation, CSL362 combined with donor-derived NKs effectively dissolved these cells, suggesting that CSL362 can be used as a promising therapy for chemotherapy and transplantation ([@B45]). Another antibody SL-101, which is a novel antibody-conjugate comprising an anti-CD123 single-chain Fv fused to *Pseudomonas exotoxin A*, is also in the preclinical study ([@B46]).

Anti-CLL-1 Antibody
-------------------

CLL-1 is a type II transmembrane glycoprotein of myeloid differentiation antigen, which is highly expressed in AML blasts and LSCs ([@B13], [@B47]). Unlike other targets such as CD33 and CD123, CLL-1 is not expressed on normal HSCs, which can ensure hematopoietic recovery, therefore provide a potential therapeutic target for AML treatment ([@B48]).

### CLL-1 ADC

CLL-1 ADC is an anti CLL-1 antibody that contains a highly potent PBD dimer DNA alkylating and cross-linking agent, conjugated through a novel self-immolative disulfide linker, which is very effective in eliminating xenografts in mice or monkey leukemia cells and has little toxicity. It is expected to be an effective and safe treatment for AML ([@B49]).

Other antibodies against AML include Hu8F4 (T-cell receptor-like monoclonal antibody binding PR1/HLA-A2 complex on the surface of AML cells), VEGF-C (Vascular Endothelial Growth Factor-C) antibody ([@B50]--[@B53]).

Selected trials of antibody directed therapy for AML has been completed or is ongoing as shown in [Table 1](#T1){ref-type="table"}.

###### 

Selected completed or ongoing trials of antibody directed therapy for AML.

  **Target**   **Biological**          **Clinical trials**   **Purpose**               **Patients**                                **Intervention/Treatment**                            **Status**   ***N***   **Phase**   **Results**
  ------------ ----------------------- --------------------- ------------------------- ------------------------------------------- ----------------------------------------------------- ------------ --------- ----------- ----------------------------------------------------------------------------------------------------------
  CD33         GO                      NCT00085709           Efficacy                  Newly diagnosed younger AML.                Induction 7+3 +/-- GO                                 Completed    637       III         The CR rate was 69% for DA+GO group and 70% for DA group (*P* = 0.59). DFS was not improved with GO
                                       NCT00372593           Efficacy                  0--29 years newly diagnosed AML             Induction 7+3 +/-- GO and post-consolidation +/--GO   Completed    1070      III         GO improved EFS (3 years: 53.1% vs. 46.9%; *P* = 0.04) but not OS (3 years: 69.4% vs. 65.4%; *P* = 0.39)
                                       NCT00551460           Efficacy                  Adult, older previously untreated HR APL    ATRA + GO + Arsenic                                   Completed    78        II          3 Years CR 74% (95% CI: 62 to 84%).
                                       NCT00895934           Efficacy and safety       50 years and older R/R AML                  Vorinostat+Azacitidine+GO                             Completed    52        I/II        ORR 41.9% (95% CI: 27.0--57.9%)
                                       NCT01409161           Efficacy and safety       10 years and older APL                      Tretinoin and arsenic +/-- GO                         Recruiting   150       II          No results
                                       NCT03287128           Efficacy and safety       18 years and older R/R AML                  GO 3 or 6 mg/m^2^                                     Recruiting   300       None        No results
                                       NCT03737955           Efficacy and safety       MRD in AML                                  Fractionated GO                                       Recruiting   36        II          No results
               SGN-CD33A               NCT01902329           Safety                    AML                                         SGN-CD33A + Azacytidine/Decitabine                    Completed    195       I           Recommended dose of SGN-CD33A is 40 μg/kg
               SGN-CD33A               NCT02785900           Efficacy                  Older Newly Diagnosed AML                   SGN-CD34A + Azacytidine/Decitabine                    terminated   240       III         Due to safety; A higher deaths rate.
  CD123        CSL360                  NCT00401739           Safety and tolerability   R/R or HR AML                               CSL360                                                Completed    40        I           No results
               CSL362                  NCT01632852           Safety                    CD123+ AML in remission                     CSL362                                                Completed    30        I           No results
               CSL362 (JNJ-56022473)   NCT02472145           Efficacy and safety       AML ineligible for intensive chemotherapy   CSL362+ Decitabine                                    Completed    326       II/III      CR rate of experimental and control group was 16.6 and 11.9%, and OS was 5 and 7 months
  PR1/HLA-A2   Hu8F4                   NCT02530034           Safety                    Advanced HM                                 Anti-PR1/HLA-A2 (Hu8F4)                               Recruiting   60        I           No results
  VEGF-C       Anti-VEGF-C             NCT01195506           Functions, mechanisms     AML                                         Anti-VEGF-C                                           Unknown      40        None        No results
  FLT3         FLYSYN                  NCT02789254           Safety, efficacy,         AML with MRD                                Fc-optimized FLT3 Antibody                            Recruiting   28        I/II        No results
  KIR          IPH2101                 NCT01256073           Safety and tolerability   60--80 years AML                            Fully human anti-KIR antibody                         Completed    21        I           No results

*AML, Acute Myeloid Leukemia; APL, Acute Promyelocytic Leukemia; CI, Confidence Interval; CR, Complete Remission; GO, Gemtuzumab Ozogamicin; HM, Hematologic Malignancies; MRD, Minimal Residual Disease; ORR, Overall response rate; R/R, relapsed/refractory*.

Anti-CD20 Antibody
------------------

CD20, a non-glycosylated transmembrane phosphoproteinis, is a B-lineage specific antigen expressed on both normal and malignant cells during nearly all stages of B-cell differentiation, but not expressed on hematopoietic stem cells, pro-B cells and plasma cells ([@B54]). It has an important role in cell cycle progression, differentiation, and modulation of apoptosis pathways ([@B55]).

### Rituximab

A chimeric antibody targeting CD20 containing a murine variable region and a human Fc region. In the study of Thomas et al. ([@B56]) to investigate the impact of addition of rituximab to the modified hyper-CVAD regimen, Hyper-CVAD combined with Rituximab could improve the outcome of young CD20 positive Ph(--) B-ALL patients, with the complete remission duration 70% vs. 38% in 3 years, OS 75% vs. 47% in 3 years, but it did not improve the survival of elderly patients ([@B56]). In a randomized Graall-R 2005 Study to evaluate the addition of rituximab to a conventional chemotherapy backbone in 209 patients ages 18 to 59 years with newly diagnosed CD20-positive Ph-negative B-cell ALL, results showed that the cumulative incidence of relapse (CIR) was decreased by Rituximab (2 years CIR 18% vs. 30.5%, *p* = 0.02), but OS was not longer (2 year OS, 71% vs. 64%; *p* = 0.095). Rituximab enhances the efficacy of chemotherapy without additive toxicity, but the improvement in the treatment of ALL is modest ([@B57]--[@B59]).

### Ofatumumab

A second generation anti CD20 monoclonal antibody that binds to a site different than Rituximab. Ofatumumab is more effective than Rituximab in inducing cytotoxic mediated by ADCC and CDC. In 55 patients with newly diagnosed ALL and 4 patients with CR who underwent a median of 8 cycles of Ofatumumab, the results showed that with the exception of 1 patient, other patients (98%) achieved CR after the first cycle, and 53 patients (93%) obtained MRD negative, and 3 year CRD and OS were 78 and 68%, respectively. The OS of patients with CD20 \< 20% and ≥20% in 3 years were 82 and 64%, respectively (*p* = 0.96) ([@B60]). It was confirmed to be safe and highly effective in patients with CD 20 positive ALL.

Anti-CD22 Antibody
------------------

CD22 is expressed in early stages of B-cell development until terminal differentiation except for plasma cells and expressed in most (\>90%) patients with B-cell ALL ([@B61]). When CD22 binds to the monoclonal antibody, antibody/antigen complex will be rapid internalization leading to antitumor effect ([@B62]).

### Epratuzumab

An unconjugated human monoclonal antibody that binds to the third extracellular domain of CD22. The combination of CD 22 with Epratuzumab results in the direct phosphorylation of upstream inhibition receptors of BCR signaling ([@B63]). The tolerance of Epratuzumab combined with reinduction chemotherapy is good, but compared with chemotherapy alone, the rate of CR2 is not significantly improved. Although increasing the times of Epratuzumab, MRD still has no significant improvement ([@B64]). In the SWOG S0910 study, for adult r/r pre-B ALL, the total effective rate (CR + PR) of the adult r/ r pre-B ALL was 52% when Epratuzumab combined with clofarabine and cytarabine, significantly higher than the previous efficacy of clofarabine/cytarabine alone (17%) ([@B65]). In the multicenter prospective phase II study of Hyper-CVAD combined with Epratuzumab for young r/r CD22 pre-B ALL, almost half of the patients were MRD negative. It is expected to improve the survival of patients if it is used in first-line therapy especially before allogeneic hematopoietic stem cell transplantation because of Epratuzumab\'s ability to reduce MRD levels ([@B66]).

### Inotuzumab Ozogamicin (InO)

A humanized anti-CD 22 ADC combined with calicheamicin, a cytotoxic antibiotic agent ([@B67]). After InO binds CD22 then internalizes itself rapidly, the conjugated calicheamicin was delivered intracellularly causing double-strand DNA cleavage and cell apoptosis. In a phase III clinical trial involving 326 r/r ALL patients to compare with InO and standard care, patients were randomly divided into InO group and standard intensive chemotherapy group ([@B67]). The complete remission rate in InO group was significantly higher than that in standard treatment group (80.7% \[95% CI, 72.1--87.7\] vs. 29.4% \[95% CI, 21.0--38.8\], *p* \< 0.001). The MRD negative rate in InO group was significantly increased (78.4% vs. 28.1% *P* \< 0.001). PFS in InO group was prolonged (median PFS: 5.0 months \[95% CI, 3.7\~5.6\], 1.8 months \[95% CI, 1.5\~2.2\]), and median OS was 7.7 months (95% CI, 6.0--9.2) vs. 6.7 months (95% CI, 4.9\~8.3). InO significantly improved the remission rate in patients with higher CD22 levels (≥90%) and lower CD22 levels (\<90%). It is worth noting that InO has a good response rate to both high and low tumor loads, while Blinatumomab has a relatively good response rate to patients with low tumor load.

Anti-CD52 Antibody
------------------

CD52 is a glycoprotein linked to the cell membrane by a phosphatidylinositol glycan linkage, and is expressed on the surface of nearly all normal and malignant B-lymphocytes and T-lymphocytes, monocytes, and macrophages, but not on plasma cells and HSCs ([@B68]). It was reported CD52 played a role in cell lysis via ADCC, complement-mediated cell lysis, and possibly apoptosis ([@B69]).

### Alemtuzumab

Alemtuzumab is a recombinant DNA-derived humanized monoclonal antibody that targets CD52. Binding to CD52 induces cell lysis through complement activation and ADCC ([@B70]). Single drug Alemtuzumab has limited effect on relapsed or refractory acute leukemia. In phase I study of CALGB, the use of Alemtuzumab after remission can eradicate MRD, but it is also associated with viral infection ([@B71]). Studies have shown that low-dose Alemtuzumab before transplant may efficiently prevent severe acute and chronic GVHD by its T-cell depleting effect ([@B72], [@B73]).

Anti-CD19 Antibody
------------------

CD19 appears at early stages and persists through all stages of B-cell maturation and is homogeneously expressed on malignant cells. It is one of the important membrane antigens involved in the activation and proliferation of B cells.

### SAR 3419

A humanized anti-CD 19 ADC that binds to a derivative of the potent microtubule-acting cytotoxic agent, Maytansin, which induces cell cycle arrest and apoptosis ([@B74]). In the study of xenotransplantation of CD19 preB ALL and mixed lineage leukemia (MLL) in mice, SAR3419 delayed the progression of the disease ([@B75]). However, in the multicenter, single-arm phase II clinical trial in patients with r/r ALL, only 4 of the 17 evaluable patients responded (ORR was 25.5%) and duration of response was only 1.9 months ([@B76]). Because of its unsatisfactory therapeutic response, the clinical trial was terminated earlier suggesting that SAR3419 monotherapy is not ideal for r/r ALL.

### SGN-CD19A

A humanized ADC targeting CD 19 linked to microtubule interfering agent monomethyla-uristatin F, which inhibits microtubule assembly, triggers cell-cycle arrest of G2-M phase growth and induces cell apoptosis. In the study of exploring SGN-CD19A safety in the treatment of r/r B-ALL and Lymphoma, the phase I clinical trial study showed good tolerance to SGN-CD19A. The objective response rate was 30% in 33 patients who could be evaluated (NCT01786096).

### SGN-CD19B

A highly active ADC proved by preclinical studies, targeting CD 19 based on Pyrrolidine diazepine, which releases DNA crosslinkers instead of microtubules inhibitors. *In vivo* experiments on monkeys, SGN-CD19B effectively cleaned CD20 B lymphocytes from peripheral blood and lymphoid tissues. Phase I clinical trials are under way to explore the therapeutic potential of SGN-CD19 in r/r B-NHL.

Selected trials of antibody directed therapy for ALL has been completed or is ongoing as shown in [Table 2](#T2){ref-type="table"}.

###### 

Selected completed or ongoing trials of antibody directed therapy for ALL.

  **Target**   **Biological**          **Clinical trials**   **Purpose**               **Patients**                                              **Intervention/ Treatment**                            **Status**   ***N***   **Phase**   **Results**
  ------------ ----------------------- --------------------- ------------------------- --------------------------------------------------------- ------------------------------------------------------ ------------ --------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CD20         Rituximab (R)           NCT00427791           Efficacy                  Up to 60 years ALL                                        Etoposide + TBI +/--R                                  Completed    23        II          Median PFS was 4.3 months for R group and 12.5 months for control group
                                       NCT00199004           Efficacy and safety       15--65 years standard risk ALL                            Chemotherapy +R                                        Completed    60        IV          No results
                                       NCT01358253           Efficacy and safety       CD20+ adult ALL                                           Hyper CVAD+/--R                                        Completed    100       IV          No results
                                       NCT01085617           Efficacy                  PreB-ALL                                                  Chemotherapy +/-- R                                    Recruiting   811       III         No results
               Ofatumumab              NCT02199184           Efficacy                  Newly diagnosed or R/R Burkitt leukemia or ALL            DA-EPOCH + Ofatumumab                                  Recruiting   40        II          No results
  CD22         Epratuzumab             NCT00098839           Efficacy                  2--31 years relapsed CD22-positive ALL                    Epratuzumab once weekly or twice weekly                Completed    134       II          For Epratuzumab once weekly or twice weekly, CR2 rate was 0.646 and 0.660, EFS rate at 4 months was 0.604 and 0.640. Rate of MRD \<0.01% at the end of Block 1 was 0.195 and 0.295
               InO                     NCT01564784           Efficacy                  Adults R/R ALL                                            InO vs. standard chemotherapy                          Completed    326       III         For InO group and standard-therapy group, CR rate was 80.7% vs. 29.4% (*P* \< 0.001), median PFS was 5.0 months vs. 1.8 months (*P* \< 0.001); median OS was 7.7 months vs. 6.7 months (*P* = 0.04)
                                       NCT03150693           Efficacy                  18--39 years newly diagnosed preB- ALL                    Frontline chemotherapy +/-- InO                        Recruiting   310       III         No results
                                       NCT03441061           Efficacy                  18 years and older B-ALL with positive MRD                InO                                                    Recruiting   40        II          No results
               Moxetumomab pasudotox   NCT00659425           Safety                    6 months to 25 years R/R CD22+ ALL or NHL                 Moxetumomab Pasudotox                                  Completed    57        I           Moxetumomab pasudotox was proved safety and activity in R/R ALL
  CD52         Alemtuzumab             NCT00061048           Efficacy and safety       ATL                                                       Alemtuzumab                                            Completed    29        II          Markedly additive antitumor activity
                                       NCT02689453           Efficacy and safety       18 years and older R/R chronic and acute ATL              IL-15 + Alemtuzumab                                    Recruiting   30        I           No results
  CD19         SGN-CD19A               NCT01786096           Safety and tolerability   1 year and older B- ALL and highly aggressive lymphomas   SGN-CD19A once or twice every 21 days (0.3--6 mg/kg)   Completed    92        I           No results

*ALL, Acute lymphoblastic leukemia; ATL, Adult T-Cell Leukemia; EFS, Even;t-free Survival; MRD, Minimal Residual Disease; InO, inotuzumab ozogamicin; HR, hazard ratio; NHL, non-Hodgkin lymphoma; TBI, Total Body Irradiation; R/R, relapsed/refractory*.

Bispecific Antibody/Trispecific Antibody {#s3}
========================================

Bi- and trispecific antibodies, are single chain variable fragment (Scfv) consisting of at least two different specific antibodies one for tumor-associated surface antigens and the other for surface antigens on effector cells, such as CD3 ε on T cells or CD16 on NK cells. Through the double specificity of BiTE, the tumor cells were combined with T effector cells in HLA-independent manner.

CD3/CD33 Bispecific T-Cell Engagers (BiTE)
------------------------------------------

### AMG 330

CD3/CD33 BiTE antibody is dual specificity for CD3 and the sialic acid-binding lectin CD33. The cytotoxicity of AMG 330 to AML cells can be mediated not only by T cells, but also by killing CD33 MDSCs ([@B77]). In the presence of AML cells, AMG 330 specifically induced expression of CD69 and CD25 as well as release of IFN-γ, TNF, interleukin (IL)-2, IL-10, and IL-6 ([@B78]). AMG 330 can overcome some limitations of CD 33 targeted drugs. It neither regulates the expression of CD 33 nor is affected by the activity of ABC transporter. The density of target antigen, the dose of antibody and the ratio of E/T are the key factors to determine the effect of BiTE ([@B79]). The results showed that T cell ligands could regulate AMG 330, and inhibitory ligands PD-L1 and PD-L2 decreased the cytotoxicity of AMG 330, while the activated ligands CD 80 and CD 86 enhanced the cytotoxicity of AMG 330. The synergistic therapy with the regulation of T cell receptor signal can further enhance the effect of this targeted therapy ([@B80], [@B81]). The expression of CD 33 and splicing polymorphism are also associated with the cytotoxicity of AMG 330 *in vitro* ([@B82]). A phase I clinical study of AMG 330 for r/r AML is ongoing (NCT02520427).

### AMG 673

An extended half-life BiTE. At present, there is no pre-clinical data report on AMG 673, but clinical research on r/r AML is being carried out (NCT03224819).

### CD33/CD3 TandAbs

CD 33/CD3 directional tandem tetravalent bispecific antibody (TandAbs). These antibodies provide two binding sites for each antigen to maintain the affinity of a bivalent antibody. Its molecular weight exceeds the renal clearance threshold, so it has a longer half-life than the smaller antibody structure. This TandAbs can induce strong, dose-dependent cell lysis in CD 33 AML cells. This effect is regulated by the ratio of effector cells to target cells, and the existence of T cells is strictly required. The activation, proliferation and maximal AML cell lysis of T cells were related to the high affinity of CD 33 and CD3. High affinity TandAbs has a wide range of activity *in vitro* in primary or r/r AML patients. Delayed and inhibited tumor growth was observed in HL-60 xenotransplantation model of immunodeficient mice. CD 33/CD3 TandAbs is the potential of a new approach to the treatment of AML ([@B83]).

CD16/CD33 Bispecific Killer Engagers (BiKE)/Bispecific Killer Engagers (TriKE)
------------------------------------------------------------------------------

### CD16/CD33 BiKE

CD16/CD33 BiKE was also named "1633" which can induce the cytotoxicity of NK cells to human AML cells by eliminating MDSCs and reverse the MDSC mediated immunosuppression of NK cells ([@B84], [@B85]). When incubated with AML cells, CD16/CD33 BiKE is able to specifically trigger the cytotoxicity and cytokine release of NK cells. CD16/CD33 BiKE can overcome the autoinhibitory signal and effectively induce the inhibitory effect of NK cell effector on AML. *In vitro*, CD16/CD33 BiKE ± ADAM 17 inhibitor enhances the activation and specificity of NK cells to CD 33 (+) AML, and may be used for recurrent AML or post-transplant anti-leukemia therapy in the future ([@B85]).

### 161533 TriKE

Although "1633" has anti-tumor effects, it lacks the ability to induce proliferation of NK cells. IL-15 plays an important role in the proliferation and activation of NK cells. Therefore, a Trike, including a modified IL-15 crosslinking agent between CD 16 and CD 33 single-chain Fv fragments (ScFvs), named "161533" was developed, this structure is capable of inducing NK cells proliferation and survival while allowing CD33-specific cytotoxic activity ([@B86]). Clinical trial of CD16/IL-15/CD33 Trikes in the treatment of high-risk heme malignancies is currently underway (NCT03214666).

CD3/CD123 Dual-Affinity Re-Targeting (DART)
-------------------------------------------

### MGD006

#### CD3CD123-DART

DART is composed of two antigen-binding specific (A+B) heavy chains and light chain variable regions on two independent polypeptide chains (VLA-VHB-VLB-VHA), and is stabilized by another C-terminal bridge ([@B87]). MGD006 is a bispecific molecule that recognizes CD3 and CD123 membrane proteins, redirecting T cells to kill CD123-expressing cells, which can induce the activation and expansion of T cells and mediate the rapid clearance of AML ([@B88]). It kills AML cells and primary AML cells in a dose-dependent manner, and the safety and effectiveness are also verified in monkey ([@B89], [@B90]). Phase I clinical studies have been conducted on the safety of MGD006 in the treatment of r/r AML or intermediate-2/high-risk MDS (NCT02152956).

### XmAb14045

A uniquely structured anti-CD123 T cell recruitment antibody developed by Xencor. XmAb technology ensures structural stability and prolongs serum half-life by retaining inactive FC fractions. The safety and toxicity of XmAb14045 were evaluated in patients with CD123+ hematologic malignancies in phase 1 I clinical study (NCT02730312).

CD3/CLL1 BiTE
-------------

CLL-1 is highly expressed in AML blasts and LSCs. Unlike other targets such as CD33 and CD123, CLL-1 is not expressed on normal HSCs, which can ensure hematopoietic recovery ([@B48]). The double-specific CLL-1/CD3 antibody (MCLA-117), a full-length human IgG1 bispecific antibody, lacking Fc effector function and containing a common light chain, was developed. MCLA-117 is able to induce target antigen-specific cytotoxicity of allogeneic or autologous T cells to primary AML cells at low E:T ratio. Phase I clinical study incorporating all subtypes of adult r/r AML and newly diagnosed, high-risk cytogenetic elderly AML to verify the safety, toxicity and efficacy of MCLA-117(NCT03038230). Other studies on CLL1 BiTE, such as CD3/CLL1 TDB (T cell-dependent bispecific), a full length human IgG1 bispecific antibody engineered for improved pharmacokinetic and altered Fc-mediated functions could extended half-lives, have shown that it has good PK properties and antitumor activity, and has little effect on the non-target of HSC ([@B48]).

CD3/CD19 BiTE
-------------

### Blinatumomab (AMG103)

A BiTE immunotherapy with dual specificity for CD19 and CD3. Blinatumomab simultaneously binds CD3+ cytotoxic T cells and CD19+ B cells and redirects T cells to lyse malignant cells ([@B91]). First of all, the phase I clinical study of MRD positive B-ALL treated with Blinatumomab was carried out. The results showed that Blinatumomab had a good response to B-ALL regardless of MRD after hemotherapy ([@B92]). A subsequent phase II clinical study of r/r preB-ALL indicated that Blinatumomab significantly increased ORR and OS. After Blinatumomab 2 cycles, ORR was 69% and the median survival time was 9.8 months ([@B93]). In a multi-center, single-arm, phase II clinical study to observe the safety and efficacy of Blinatumomab in the treatment of adult r/r preB-ALL, the adverse reactions were mainly granulocytopenia fever and controlled neurotoxicity. The CR rate was 32% \[95% CI, 26%\~40%\] and the median remission time was 6.7 months. About 31% (95% CI, 25%\~39%) of the patients had MRD response ([@B94]). Based on the above research, FDA approved the application of Blinatumomab to Ph(--) r/r preB-ALL on December 3, 2014. There are many clinical studies on Blinatumomab, including the phase III clinical study of Blinatumomab for the first/second recurrence of ALL, the phase II clinical trial for recurrent Ph + ALL and the first-line treatment for MRD + ALL. In a study of 405 preB-ALL patients who received a large number of previous pretreatments, patients were randomly divided into single drug Blinatumomab group and standard chemotherapy group. The results showed that the median survival time of Blinatumomab group was significantly better than that of chemotherapy group (7.7 months vs. 4.0 months) ([@B95]). In the adult r/r preB ALL treated with Blinatumomab, the OS of the patients with MRD reaction was significantly longer than that of the patients without MRD reaction, and the T cell amplification was found to be larger in the long-term survivors. It suggests that the long-term survival of the patients may be related to the MRD reaction and the high expansion of T cells ([@B96]).

CD3/CD20 BiTE
-------------

### CD20-TDB

B cells targeting anti-CD20/CD3 T cell dependent bispecific antibody (CD20-TDB), is a full-length humanized immunoglobulin G1 molecule. In monkeys, CD20-TDB at a single dose of 1 mg/kg can effectively kill B cells in peripheral blood and lymphoid tissues and exhibit pharmacokinetic characteristics similar to those of conventional monoclonal antibodies ([@B97]).

CiTE
----

One mechanism of limiting BiTE activity may be T cell incompetence and exhaustion driven by PD-1/PD-L1 and so on. Blocking the PD-1/PD-L1 pathway can increase the cytotoxicity of CD33/CD3 BiTE to leukemia cells ([@B81]). Herrmann et al. fused the PD-1 extracellular domain (PD-1EX) with CD3 × CD 33 BiTE to form CiTE. Studies have shown that CiTE with PD-1EX domain increases the specificity. Early clinical trials are under way. If preliminary trials prove to be free of severe immune-related adverse events, this could be an important step forward ([@B98], [@B99]).

Selected trials of bispecific or Tri-Specific T cell or killer Engagers antibody directed therapy for AML and ALL has been completed or is ongoing as shown in [Table 3](#T3){ref-type="table"}.

###### 

Selected completed or ongoing trials of bispecific or Tri-Specific T cell or killer Engagers antibody directed therapy for AML and ALL.

  **Target**   **Biological**              **Clinical trials**   **Purpose**                          **Patients**                                                                                **Intervention/Treatment**                                     **Status**           ***N***   **Phase**   **Results**
  ------------ --------------------------- --------------------- ------------------------------------ ------------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------- --------- ----------- ---------------------------------------------------------------------
  CD3/CD33     AMG 330                     NCT02520427           Safety and tolerability              R/R AML                                                                                     AMG330 0.5--960 μg/day infusion in cycles from 14 to 28 days   Recruiting           70        I           No results
               AMG 673                     NCT03224819           Safety and tolerability              18 years and older R/R AML                                                                  AMG 673                                                        Recruiting           50        I           No results
               JNJ-67371244                NCT03915379           Safety and tolerability              R/R AML or MDS                                                                              JNJ-67371244                                                   Recruiting           90        I           No results
               CD33/CD3 TandAbs (AMV564)   NCT03144245           Safety and tolerability              18 years and older R/R AML                                                                  AMV564                                                         Recruiting           148       I           No results
  CD16/CD33    161533 TriKE                NCT03214666           Safety and tolerability              HR heme malignancies, R/R AML and advanced SMCD                                             161533 TriKE                                                   Not yet recruiting   60        I/II        No results
  CD3/CD123    MGD006                      NCT02152956           Safety and tolerability              R/R AML or intermediate-2/high risk MDS                                                     Flotetuzumab (MGD006)                                          Recruiting           179       I/II        No results
               XmAb14045                   NCT02730312           Safety and tolerability              18 years and older CD123+ hematologic malignancies                                          XmAb14045                                                      Recruiting           105       I           No results
               JNJ-63709178                NCT02715011           Safety and tolerability              18 years and older R/R AML                                                                  JNJ-63709178                                                   Recruiting           60        I           No results
  CD3/CLL1     MCLA-117                    NCT03038230           Safety and tolerability              18 years and older AML                                                                      MCLA-117                                                       Recruiting           50        I           No results
  CD3/CD19     Blinatumomab                NCT02877303           Efficacy                             Adults with B-ALL                                                                           Hyper-CVAD + Blinatcumomab as frontline therapy                Recruiting           60        II          No results
                                           NCT03982992           Efficacy, safety, and tolerability   18 years and older treatment-resistant mixed chimerism or MRD of preB-ALL after Allo-HSCT   Blinatumomab+ donor lymphocyte infusion                        Recruiting           12        II          No results
                                           NCT01466179           Efficacy and safety                  18 years and older Ph-, primary R/R leukemia                                                Blinatumomab                                                   Completed            225       II          After two cycles Blinatumomab, CR+CRh rate was 43% (95% CI: 36--50)
                                           NCT01207388           Efficacy, safety, and tolerability   18 years and older ALL patients with MRD                                                    Blinatumomab 15 μg/m^2^/day for 4 cycles                       Completed            116       II          After 1 cycle of Blinatumomab, complete MRD response was 78%
                                           NCT02000427           Efficacy                             18 years and older Ph+ ALL R/R to TKI                                                       Blinatumomab                                                   Completed            45        II          36% (95% CI, 22 to 51%) achieved CR/CRh after the first two cycles

*ALL, Acute lymphoblastic leukemia; Allo-HSCT, Allogeneic hemopoietic Stem Cell Transplantation; AML, Acute Myeloid Leukemia; HR, High Risk; MDS, Myelodysplastic Syndrome; MRD, minimal residual disease; Ph(--), Philadelphia-chromosome negative; R/R, relapsed/refractory; SMCD, Systemic mast cell disease (Systemic Mastocytosis)*.

Chimeric Antigen Receptor (CARs) {#s4}
================================

CARs are genetically engineered cell membrane binding receptors which can activate T cells by linking from the extracellular antigen binding region to the intracellular signal domain via the spacer, whose effect on target antigen is independent of MHC ([@B100]). Genetic material encoding the chimeric antigen receptor is transferred into the patient\'s T cells using transfection, gamma retroviral or lentiviral recombinant vectors, or a transposon system ([@B101]--[@B104]). The advantages and limitations of each approach have not been fully elucidated recently. CARs contain an extracellular tumor antigen-recognizing scFv linked to an intracellular signaling component comprised of T-cell receptor (TCR) primary domain and often encompassing additional co-stimulatory endodomains (e.g., CD28, CD137 (4-1BB), CD134 (OX40), CD27, ICOS, etc.) ([@B105]). CAR transmits a signal by its ligand to the intracellular T cells through a signaling domain, typically the CD3-Zeta chain. The incorporation of co-stimulatory molecules can augment the effects of zeta chain signaling and hence enhance T cell proliferation and persistence ([@B106]). According to co-stimulators in signal transduction domain, CAR could be divided into four generations. The first-generation CAR T cells lacked co-stimulatory molecules and had little anti tumor activity ([@B107]). The second-generation CARs contain one co-stimulatory signaling domain CD28 or 4-1BB and the third-generation CARs contain two co-stimulatory signaling domains, with the first consisting of a CD28 or 4-1BB domain and the second provided by other molecules, such as OX40, CD28, or 4-1BB ([@B105]). Whether third generation CARs benefit more than second generation CARs remains unknown ([@B108]). Recent preclinical results indicate that CD137-based co-stimulatory domains are better than those based on CD28 at preventing T cell exhaustion ([@B109]). In recent years, the fourth-generation "armored CAR" T cells are engineered to additionally express cytokines or co-stimulatory ligands, aimed at enhancing expansion and longevity of the CAR T cells ([@B110]). Optimization of CARs design is an effective way to improve anti-tumor effect.

CD33 CART
---------

### CD33 CART

Wang et al. demonstrated that CD33 CAR-T cells exhibited potent antileukemic efficacy, and CAR-T cells with 4-1BB co-stimulatory ligands performed better in antileukemic function than with CD28. Further analysis showed that CD33 4-1BBz.CAR-T cells had an increased central memory compartment and showed resistance to exhaustion ([@B111]). In NSG mice model of AML xenotransplantation, a novel second-generation anti-CD33 CAR that incorporates a 4-1BB-CD3ζ signaling tail, CD 33 CART can significantly reduce tumor load and prolong survival time ([@B112]). But it also causes toxic effects on normal hematopoietic cells. In order to reduce the toxicity, SS Kenderian et al. designed a transient expression of mRNA anti-CD33 CAR ([@B113]). Recently published in Cell, using genetic engineering to inactivate the CD33 gene of HSCs can avoid the toxic effect of CD33 CART on bone marrow, thus making it possible for CD33 CART to treat AML ([@B114]).

CD 123 CART
-----------

CD 123 CART and CD 123-CAR cytokines induced killer cells (in which PBMC is activated by interferon γ and IL-2) have become a potential therapy for AML ([@B115], [@B116]). It is worth noting that CD 123-CART on normal hematopoietic function is smaller than that of CD33 CART. Modification of anti-CD123 scFv with VH and VL chains of different monoclonal antibodies can reduce the bone marrow toxicity of AML mice ([@B117]). The first clinical trial of CART-123 for r/r AML was conducted in our country in 2016 (NCT02937103), and there are other two trials ongoing (NCT03556982)/ (NCT03672851). Stage I clinical trials of CD123-CART for recurrent AML after Allo-HSCT are also underway (NCT03114670).

CLL1 CART
---------

### CLL1 CART

CLL-1 CART cells generated by Zhou using the scFv region of the mAb against CLL-1 coupled to the co-stimulatory domains of CD28, 4-1BB, and the CD3-ζ chain could specifically dissolve CLL-1 cells and primary AML cells *in vitro* ([@B118]). Anti-tumor activity was also observed in AML mice and the survival time of mice was prolonged. Importantly, CLL-1 CART can specifically clear CLL-1 myeloid progenitor cells and mature myeloid cells, whereas normal HSCs are unaffected by their lack of CLL-1 expression ([@B118], [@B119]).

Other potential target antigens for AML include CD44v6 ([@B120]), FR β ([@B121]), NKG2D ([@B122]), and PR1/HLA-A2 ([@B53]), and so on.

CD19 CART
---------

### CD19 CART

The CR rate of r/r ALL treated with CART19 was as high as 70--90%, and a sustained remission was observed without additional treatment ([@B123]--[@B125]). In order to improve the efficacy, the main focus is on the design of CAR. Phase I trials of 19--28z CART in 16 patients with r/r ALL showed a total CR rate of 88%, enabling most patients to transition to allo-HSCT ([@B126]). The safety and long-term results of 53 adult patients with relapsed ALL treated with 19--28z CART were evaluated. Fourteen cases developed severe cytokine release syndrome (26%) and 1 case died. Eighty three percentage of the patients achieved complete remission. Median follow-up was 29 months (range 1--65 months), median EFS was 6.1 months (95% CI, 5.0--11.5 months) and median OS was 12.9 months (95% CI, 8.7--23.4 months). In patients with low tumor load, the median OS was 20.1 months, and the incidence of cytokine release syndrome and neurotoxic events was significantly lower than that in patients with high tumor load ([@B127]). The third generation CART19 1928zT2 designed by Li Peng also achieved a good effect in the treatment of relapsed ALL ([@B128]). Besides, 4-1BB co-stimulatory signal is also engineered with the use of lentiviral-vector technology for gene transfer and permanent T-cell modification, named CTL019. After 30 patients with r/r ALL received CTL019 treatment, 27 cases (90%) received CR. The 6 months EFS was 67% (95% CI, 51\~88) and OS was 78% (95% CI, 65\~95) ([@B61]). Another study of 29 patients with r/r B-ALL treated with CD 19 4-1BB co-stimulated CART cells concluded the 86% MRD negative rate ([@B129]). FDA has granted CTL 019 breakthrough treatment status.

Compound CART
-------------

The compound of CART: 123b-33bc CAR T, targeting CD 123 and CD 33 at the same time, not only eliminate the tumor load of AML, but also prevent the recurrence caused by the escape of antigen or the persistence of LSC. It has strong antitumor activity *in vivo* ([@B130]). With regard to CD123/CLL1 CART, phase II clinical trials plan to recruit 20 patients with r/r AML younger than 70 years old to verify their safety and toxicity.

According to research, it shows that PD-1 inhibitor can regulate the CART cell responses, suggesting that the PD-1 pathway may be critical for determining the T-cell immunotherapy response of CAR-modified cells. The combination of PD-1 inhibitor and CART is except to improve the treatment response and remission time.

Selected trials of CAR cell therapy for AML and ALL has been completed or is ongoing as shown in [Table 4](#T4){ref-type="table"}.

###### 

Selected completed or ongoing trials of CAR cell therapy for AML and ALL.

  **Target**     **Biological**                                 **Clinical trials**   **Purpose**               **Patients**                             **Intervention/Treatment**                                                                                                                  **Status**   ***N***   **Phase**   **Results**
  -------------- ---------------------------------------------- --------------------- ------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------ --------- ----------- -----------------------------------------
  CD33           CD33-CAR-T                                     NCT03126864           Safety and tolerability   1--80 years CD33+ R/R AML                CD33-CAR-T cell infusion                                                                                                                    Recruiting   39        I           No results
  CD123          UCART123                                       NCT03190278           Safety and activity       R/R AML, and newly diagnosed HR AML      UCART123                                                                                                                                    Recruiting   162       I           No results
                 CD123 CAR/28,EGFRt+ T cells                    NCT02159495           Safety and tolerability   R/R AML and persistent/recurrent BPDCN   Autologous or allogeneic CD123+ CAR T cells                                                                                                 Recruiting   42        I           No results
  Compound CAR   CLL1-CD33 CART                                 NCT03795779           Safety and tolerability   R/R HR hematologic malignancies.         CLL1-CD33 compound CAR T cells                                                                                                              Recruiting   20        I           No results
                 CD123/CLL1 CART                                NCT03631576           Safety and tolerability   R/R AML.                                 CD123/CLL1 compound CAR-T Cells                                                                                                             Recruiting   20        II/III      No results
  CD19           CD19 CAR/137 T cells                           NCT02030847           Efficacy and safety       R/R B-ALL                                Single infusion of autologous CD19 CAR T cells                                                                                              Completed    42        II          CR+CRi was 60% at Day 28 after infusion
                 huCART19                                       NCT03792633           Efficacy                  1--29 years VHR B-ALL                    huCART19 infusion                                                                                                                           Recruiting   85        II          No results
                 CARCIK-CD19                                    NCT03389035           Safety and tolerability   1--75 years R/R B-ALL After HSCT         CARCIK-CD19 (Allogeneic CIK cells transduced with a transposon CD19 CAR gene)                                                               Recruiting   18        I/II        No results
                 CD19 CAR/137 T cells                           NCT02965092           Efficacy and safety       R/R B-cell Malignancies                  CAR-T cells                                                                                                                                 Recruiting   80        I/II        No results
                 KTE-C19                                        NCT02625480           Safety and efficacy       2--21 years R/R preB-ALL                 Fludarabine and Cyclophosphamide followed infusion of KTE-C19                                                                               Recruiting   100       I/II        No results
                 CD19.CAR/28 T cells, CD19.CAR/28.137 T cells   NCT01853631           Safety and efficacy       Advanced B-NHL, ALL and CLL              CD19.CAR/28 T cells and CD19.CAR/28.137 T cells +/-- Cyclophosphamide and Fludarabine                                                       Recruiting   64        I           No results
                 CD19 CART                                      NCT02146924           Safety and efficacy       18 years and older high-risk CD19+ ALL   1.CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes; 2.CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes   Recruiting   88        I           No results
  CD20           CD20 CART                                      NCT02710149           Safety and efficacy       14--75 years B cell malignancies         CD20-targeted CAR-T cells                                                                                                                   Recruiting   45        I/II        No results
                 CD20/CD22/CD10-CART                            NCT03407859           Safety and efficacy       18--60 years R/R B-ALL                   Sequential treatment with CD20/CD22/CD10-CART after CD19-CART treatment                                                                     Recruiting   30        I           No results
  CD22           CD22 CART                                      NCT03262298           Safety and efficacy       18--65 years B cell malignancies         Anti-CD22-CAR-transduced T cells                                                                                                            Recruiting   20        I/II        No results
  Compound CAR   CD19 and CD20 or CD22 CART                     NCT03398967           Safety and efficacy       R/R leukemia and lymphoma                Universal dual specificity CD19 and CD20 or CD22 CAR-T cells                                                                                Recruiting   80        I/II        No results
                 CD19/20-CART                                   NCT03097770           Safety and efficacy       R/R B-cell leukemias and lymphomas       Anti-CD19/20-CAR vector-transduced T cells                                                                                                  Recruiting   20        None        No results
                 AUTO3                                          NCT03289455           Safety and activity       1--24 years R/R B-ALL                    AUTO3 (CD19/22 CAR T cells)                                                                                                                 Recruiting   50        I/II        No results

*AML, Acute Myeloid Leukemia; ALL, Acute lymphoblastic leukemia; BPDCN, Blastic Plasmacytoid Dendritic Cell Neoplasm; CAR, Chimeric Antigen Receptor; CIK, Cytokine Induced Killer; CLL, Chronic Lymphocytic Leukemia; HR, High-Risk; R/R, relapsed/refractory; HSCT, Hematopoietic Stem Cell Transplantation; NHL, Non-Hodgkin\'s Lymphoma; R/R, relapsed/refractory; Tcm, central memory T cells; Tn/mem, naive and memory T cells; VHR, Very High-Risk*.

Immune Checkpoint Inhibitor and Immune Agonist {#s5}
==============================================

The two main immune checkpoint blocking pathways in clinical studies are cytotoxic T lymphocyte antigen (CTLA-4) and programmed cell death pathway. Programmed cell death pathways include programmed cell death protein 1 (PD-1) and its ligands, programmed death ligands 1 (PD-L1) and 2 (PD-L2). Although most clinical studies of blocking PD-1 and CTLA-4 with humanized monoclonal antibodies are directed at solid tumors and lymphoma, PD-1 and CTLA-4 also play a role in leukemia, GVL and GVHD ([@B131]). Blocking CTLA-4 and blocking PD-1/PD-L1 pathway with anti PD-L1 antibody enhanced the anti-leukemia immune response in mice ([@B131], [@B132]). Combined blocking of PD1/PD-L1 and Tim-3/galectin-9 may help to prevent CD8 (+) T cell failure in patients with advanced AML and other malignant hematological diseases ([@B133]). Studies have shown that epigenetic drugs can regulate the expression of immunological checkpoint molecules on TIL and tumor cells ([@B134]), such as Azacytidine upregulating the expression of PD-1 and PD-L1 in MDS/AML. The up-regulation of these genes may be related to the emergence of Azacytidine resistance and the decrease of survival time ([@B135]). To improve response rates, epigenetic drugs combined with PD-1/PDL-1 inhibitors are also being tested in clinical trials (NCT02397720, NCT02530463). The timing of immune checkpoint blocking may be more important for the occurrence of hematological malignancies, especially leukemia, because the tumor itself often destroys the host\'s immune function. Due to high tumor burden and proliferation rate in acute leukemia, the disease may develop before checkpoint antibodies (especially when used alone) have sufficient time to activate the immune response. Therefore, when there is minimal residual disease and a complete immune system, the application of immune checkpoint inhibitors may achieve the best results. A number of clinical trials are currently underway to use checkpoint antibodies as a single drug or in combination with standard chemotherapy regimens to treat newly diagnosed and relapsed leukemia patients.

OX40, a member of the tumor necrosis factor receptor family, is an activating receptor expressed on the surface of activated CD4+ T cells and CD8+ T cells. OX40 signaling activates downstream NF-κB and PI3K pathways, whose sustained activation prolongs T cell survival and promotes the activation and proliferation of T cells. OX40 also inhibits the differentiation and activity of T-reg cell and improves immunosuppressive effects thereby to reinforce antitumor immunity. Besides, OX40L signal transduction promotes NK cells activation, cytokines production, cytotoxicity and the like ([@B136]--[@B138]). OX40/OX40L has received widespread attention as a potential target for immune activation. Clinical trial of OX40 antibody to treat leukemia is ongoing (NCT03390296, NCT03410901). However, OX40 is expressed on leukemic blasts in a substantial percentage of patients with AML, and so after stimulation with OX40 agonist, OX40 can mediate proliferation and release of cytokines that act as growth and survival factors for the leukemic cells ([@B136]). Therefore, the therapeutic effect of OX40 antibody on leukemia needs further verification.

Selected trials of Immune Checkpoint Inhibitor therapy for AML and ALL has been completed or is ongoing as shown in [Table 5](#T5){ref-type="table"}.

###### 

Selected completed or ongoing trials of Immune Checkpoint Inhibitor therapy for AML and ALL.

  **Target**      **Biological**                   **Clinical trials**   **Purpose**                   **Patients**                                                                          **Intervention/Treatment**                                              **Status**               ***N***   **Phase**   **Results**
  --------------- -------------------------------- --------------------- ----------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------ --------- ----------- -------------
  PD-1            Nivolumab                        NCT02532231           Efficacy                      AML in remission at high risk for relapse                                             Nivolumab                                                               Recruiting               30        II          No results
                                                   NCT02275533           Efficacy                      AML patients after chemotherapy                                                       Nivolumab once every 2 weeks repeatedly every 2 weeks for 46 courses    Recruiting               80        II          No results
                  Pembrolizumab                    NCT03969446           Safety and efficacy           Newly-diagnosed OR R/R AML or MDS                                                     Pembrolizumab and Decitabine                                            Not yet recruiting       54        I           No results
                                                   NCT02845297           Safety and efficacy           R/R AML and in newly diagnosed older AML                                              Azacitidine and Pembrolizumab                                           Recruiting               40        II          No results
                                                   NCT03286114           Efficacy                      Relapse of primary malignancy after Allo-HSCT                                         Pembrolizumab                                                           Recruiting               20        I           No results
                                                   NCT02708641           Efficacy                      Patients ≥60 AML not transplantation candidates                                       Post-remission treatment with Pembrolizumab 200 mg once every 3 weeks   Recruiting               40        II          No results
                                                   NCT02767934           Safety and efficacy           ALL With MRD                                                                          Pembrolizumab                                                           Recruiting               21        II          No results
  PD-L1           Durvalumab                       NCT02775903           Efficacy and safety           Previously untreated HR MDS or in elderly (\> = 65 years) AML not eligible for HSCT   Azacitidine+/-- Durvalumab                                              Active, not recruiting   213       II          No results
  CTLA4           Lpilimumab                       NCT01757639           Safety and tolerability       AML With MRD                                                                          lpilimumab                                                              Completed                42        I           No results
                                                   NCT02890329           Safety and tolerability       R/R MDS/AML                                                                           lpilimumab and Decitabine                                               Recruiting               48        I           No results
  CD47 PD-L1      Hu5F9-G4 Atezolizumab            NCT03922477           Safety and pharmacokinetics   R/R AML                                                                               Hu5F9-G4 and Atezolizumab                                               Not yet recruiting       21        I           No results
  CTLA4 PD-1      Ipilimumab Nivolumab             NCT03600155           Safety and tolerability       HR or R/R AML                                                                         lpilimumab and Nivolumab                                                Recruiting               55        I           No results
                                                   NCT02397720           Safety and efficacy           R/R or newly diagnosed AML                                                            Azacitidine, Ipilimumab, Nivolumab                                      Recruiting               182       II          No results
  PD-1 TIM-3      PDR001 MBG453                    NCT03066648           Safety and tolerability       AML or HR MDS                                                                         Decitabine, PDR001, MBG453                                              Recruiting               175       I           No results
  PD-1 CD3/CD19   Pembrolizumab and Blinatumomab   NCT03512405           Safety and Efficacy           R/R ALL                                                                               Pembrolizumab and Blinatumomab                                          Recruiting               36        I/II        No results
  OX40            PF-04518600                      NCT03390296           Safety and tolerability       R/R AML                                                                               PF-04518600, Avelumab Azacitidine, Glasdegib, Venetoclax, GO            Recruiting               18        I           No results

*ALL, Acute lymphoblastic leukemia; AML, Acute Myeloid Leukemia; GO, Gemtuzumab Ozogamicin; HR, High-Risk; MDS, Myelodysplastic Syndrome; PDR001, a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1; MBG453, a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine; HSCT, Hematopoietic Stem Cell Transplantation. R/R, relapsed/refractory*.

NK Cells {#s6}
========

NK cells can exert direct cytotoxic activity without antigen-specific initiation and activate other immune cells to promote anti-leukemia immune response ([@B139]). The activity of NK cells in patients with acute leukemia is affected by a number of mechanisms, including reduced expression of activated receptors and decreased cytokine secretion ([@B140], [@B141]). In addition, the low expression of NK ligands in leukemia cells and the production of soluble immunosuppressive factor are also the reasons of impaired NK cells activity ([@B142], [@B143]). NK cell-based tumor immunotherapy strategies include anti KIR antibodies, cytokines (including IL-15 and IL-2), adoptive HLA- haploidentical NK cells and use of NK cell lines ([@B139], [@B144]--[@B146]). Other strategies include reducing Treg cells and using bispecific antibodies, such as CD16 on NK cells and leukemia cell-specific antigens, which significantly enhance the cytotoxicity mediated by antibody dependent cells, one of the main mechanisms for eliminating leukemic cells.

IL-2 diphtheria toxin fusion protein (IL2DT) can enhance the clearance of AML by haplotype NK cells. After 7 days of NK cells adoptive infusion, the depletion of Treg and the persistence of NK cells predicted a good clinical response. IL2DT could reduce the host Treg cells and then improve the efficacy of haploid NK cells in the treatment of AML ([@B147]). Cytokine induced memory like NK cells enhance its cytotoxicity to myeloid leukemia, and this effect is independent of KIR, which has been confirmed in NSG transplanted tumor model mice ([@B148]). Recent studies have shown that ATO enhances the cytotoxicity of NK cells, and the mechanism may be that ATO can change the receptor and ligand structure of NK cells ([@B149]). Samudio et al. used oncolytic virus HSV to activate peripheral blood mononuclear cells to lyse leukemia cells. This activation depends, at least in part, on TLR-2, and acts primarily by activating NK cells ([@B150]). Fc-optimized CD133 antibody (293 C3-SDIE) significantly enhanced the activation, degranulation and lysis of primary CD133-positive AML cells by allogeneic and autologous NK cells, thereby promoting the clearance of AML cells by NK cells ([@B151]). Williams et al. found that CD16 NK-92 cells combined with an antibody against leukemia stem cell antigen could improve the survival of AML model mice ([@B44]).

Selected trials of NK cells therapy and other immunotherapies for AML and ALL has been completed or is ongoing as shown in [Table 6](#T6){ref-type="table"}.

###### 

Selected completed or ongoing trials of NK cells therapy and other immunotherapies for AML and ALL.

  **Target**   **Biological**                             **Clinical trials**   **Purpose**            **Patients**                                                                                        **Intervention/Treatment**                                                                                            **Status**   ***N***   **Phase**   **Results**
  ------------ ------------------------------------------ --------------------- ---------------------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------ --------- ----------- -------------
  NK           NK Cells                                   NCT01904136           Safety, tolerability   High-risk myeloid malignancies undergoing HSCT                                                      Allo-HSCT /BMT/chemotherapy/NK cell therapy/TBI                                                                       Recruiting   90        I/II        No results
               CIML NK cell                               NCT02782546           Safety and efficacy    AML                                                                                                 Cytokine induced memory-like NK cell adoptive therapy after haploidentical donor hematopoietic cell transplantation   Recruiting   60        II          No results
               NK cells                                   NCT02185781           Safety, tolerability   Ph+ ALL in CHR but with P/R MRD ≥60 years or not eligible for other post-CHR treatment modalities   Enriched and expanded autologous NK cells infusions                                                                   Recruiting   6         I           No results
               NK cells                                   NCT00995137           Safety, tolerability   Up to 18 years B-ALL                                                                                Genetically modified haploidentical natural killer cell infusions                                                     Completed    14        I           No results
               NK cells                                   NCT01787474           Safety and efficacy    18 years and older R/R AML                                                                          IL-21-expanded natural killer cells                                                                                   Recruiting   44        I/II        No results
  Vaccine      DEC-205/NY-ESO-1 fusion protein CDX-1401   NCT03358719           Safety and efficacy    MDS or Low Blast Count AML                                                                          DEC-205/NY-ESO-1 fusion protein CDX-1401/Decitabine/Nivolumab/Poly ICLC                                               Recruiting   18        I           No results

*ALL, Acute lymphoblastic leukemia; Allo-HSCT, Allogeneic Hematopoietic Stem Cell Transplantation; AML, Acute Myeloid Leukemia; BMT, Bone Marrow Transplantation; CHR, Complete Hematologic Remission; HSCT, Hematopoietic Stem Cell Transplantation; NK cells, Natural Killer Cells; P/R, Persistent/Recurrent; R/R, relapsed/refractory; TBI, Total-B*.

Conclusions {#s7}
===========

The use of immunotherapy in the treatment of acute leukemia has greatly improved the choice of treatment. It not only provides an opportunity for hematopoietic stem cell transplantation, but also increases the MRD response rate, reduces the MRD level, and further improves the remission time and survival time. Combined use of multiple immunotherapies, such as checkpoint inhibitors combined with other immunotherapy, can improve efficacy and duration of response. Although immunotherapy exhibits a good prospect, its toxicity deserves attention. The side effects of immunotherapy on normal HSCs are urgent problems to be solved, and more precise targets need to be studied to reduce the damage to normal cells.
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